摘要
目的:观察前列腺素E1脂微球载体制剂(LIPO PGE1)治疗重型肝炎的临床疗效及其安全性。方法:选择69例重型肝炎病人给予综合治疗,35例为对照组,34例治疗组病人在综合治疗基础上加用LIPO PGE1(10μg,每日2次),疗程7～14d,此后继续综合治疗。比较两组病人及LIPO PGE1治疗前后的肝功能,肾功能及临床症状等的变化并观察LIPO PGE1的不良反应。结果:应用LIPO PCE1后肝功能好转率达61.8％;治疗重型肝炎的临床疗效方面,急性和亚急性病例优于慢性病例,早期病例优于中晚期病例;LIPO PCE1可增加合并肝肾综合征患者的尿量;不良反应发生率为17.6％。结论:在综合治疗基础上加用LIPO PGE1治疗重型肝炎有较好的疗效且较安全,早期应用效果更好。
Objectives: To observe the efficacy and safety of Lipo-Prostaglandin El (Lipo PGE1) in treatment of severe hepatitis. Methods: 69 patients with severe hepatitis were selected to receive complex therapy. To 34 patients of the therapy group Lipo PGE1 was added to the therapy with the dosage of 10μg bid for 7~14 days, and then continue the complex treatment. Liver function, renal function and symptoms after using Lipo PGE1 were compared with those before the treatment of Lipo PGE1 , and those of two groups were also compared. The categories and severity of adverse events were registered. Results: Results of liver function tests showed the rate of improvement of the therapy group was 61.8%. Results also demonstrated that the treatment of Lipo PGE1 was of better efficacy when used to the patients with acute or subacute severe hepatitis than those with chronic severe hepatitis and the efficiency of early stage cases was significantly higher than that of middle or late stage cases. In addition Lipo PGE1 could improve the amount of urine of the patients with hepatorenal syndrome. The incidence rate of adverse events was 17.6% . Conclusion: Lipo PGE1 in addition to the combined therapy is effective and safe at 10μg bid doses in the treatment of severe hepatitis and should be adopted in early stage of the disease.
出处
《中国医药导刊》
2004年第2期114-117,共4页
Chinese Journal of Medicinal Guide
